These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 1848576)
1. Expression of the human papillomavirus E7 oncogene during cell transformation is sufficient to induce susceptibility to lysis by activated macrophages. Banks L; Moreau F; Vousden K; Pim D; Matlashewski G J Immunol; 1991 Mar; 146(6):2037-42. PubMed ID: 1848576 [TBL] [Abstract][Full Text] [Related]
2. Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of the human papilloma virus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells. Hu G; Liu W; Hanania EG; Fu S; Wang T; Deisseroth AB Cancer Gene Ther; 1995 Mar; 2(1):19-32. PubMed ID: 7621252 [TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of transformation by the human papillomaviruses. Howley PM; Münger K; Werness BA; Phelps WC; Schlegel R Princess Takamatsu Symp; 1989; 20():199-206. PubMed ID: 2562182 [TBL] [Abstract][Full Text] [Related]
4. Dissimilar immunogenicities of human papillomavirus E7 and adenovirus E1A proteins influence primary tumor development. Routes JM; Ryan S; Li H; Steinke J; Cook JL Virology; 2000 Nov; 277(1):48-57. PubMed ID: 11062035 [TBL] [Abstract][Full Text] [Related]
5. The cell biology of human papillomavirus transformed cells. Matlashewski G Anticancer Res; 1989; 9(5):1447-56. PubMed ID: 2556072 [TBL] [Abstract][Full Text] [Related]
6. Transforming activity of the E6 gene of HPV-11gt in NIH 3T3 and REF 52 cells: correlation with the level of E6 transcription. Trujillo JM; Mounts P Virology; 1996 Jun; 220(1):1-9. PubMed ID: 8659100 [TBL] [Abstract][Full Text] [Related]
7. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545 [TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus type 16 E6 gene cooperates with EJ-ras to immortalize primary mouse cells. Storey A; Banks L Oncogene; 1993 Apr; 8(4):919-24. PubMed ID: 8384359 [TBL] [Abstract][Full Text] [Related]
9. Role of tumor necrosis factor-alpha in E1A oncogene-induced susceptibility of neoplastic cells to lysis by natural killer cells and activated macrophages. Cook JL; May DL; Wilson BA; Holskin B; Chen MJ; Shalloway D; Walker TA J Immunol; 1989 Jun; 142(12):4527-34. PubMed ID: 2723438 [TBL] [Abstract][Full Text] [Related]
10. The E5 gene of HPV-16 enhances keratinocyte immortalization by full-length DNA. Stöppler MC; Straight SW; Tsao G; Schlegel R; McCance DJ Virology; 1996 Sep; 223(1):251-4. PubMed ID: 8806560 [TBL] [Abstract][Full Text] [Related]
11. Elevated wild-type p53 protein levels in human epithelial cell lines immortalized by the human papillomavirus type 16 E7 gene. Demers GW; Halbert CL; Galloway DA Virology; 1994 Jan; 198(1):169-74. PubMed ID: 8259651 [TBL] [Abstract][Full Text] [Related]
12. HPV-16 oncogenes E6 and E7 are mutagenic in normal human oral keratinocytes. Liu X; Han S; Baluda MA; Park NH Oncogene; 1997 May; 14(19):2347-53. PubMed ID: 9178911 [TBL] [Abstract][Full Text] [Related]
13. Notch1 can contribute to viral-induced transformation of primary human keratinocytes. Lathion S; Schaper J; Beard P; Raj K Cancer Res; 2003 Dec; 63(24):8687-94. PubMed ID: 14695182 [TBL] [Abstract][Full Text] [Related]
14. The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer. Pillai MR; Halabi S; McKalip A; Jayaprakash PG; Rajalekshmi TN; Nair MK; Herman B Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):329-35. PubMed ID: 9162297 [TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus type 45 E7 is a transforming protein inducing retinoblastoma protein degradation and anchorage-independent cell cycle progression. Morandell D; Rostek U; Bouvard V; Campo-Fernández B; Fiedler M; Jansen-Dürr P; Zwerschke W Virology; 2008 Sep; 379(1):20-9. PubMed ID: 18649911 [TBL] [Abstract][Full Text] [Related]
16. In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma. Madrigal M; Janicek MF; Sevin BU; Perras J; Estape R; Peñalver M; Averette HE Gynecol Oncol; 1997 Jan; 64(1):18-25. PubMed ID: 8995542 [TBL] [Abstract][Full Text] [Related]
17. Cervical carcinoma cells transfected with the CD80 gene elicit a primary cytotoxic T lymphocyte response specific for HPV 16 E7 antigens. Kaufmann AM; Gissmann L; Schreckenberger C; Qiao L Cancer Gene Ther; 1997; 4(6):377-82. PubMed ID: 9408608 [TBL] [Abstract][Full Text] [Related]
18. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Münger K; Basile JR; Duensing S; Eichten A; Gonzalez SL; Grace M; Zacny VL Oncogene; 2001 Nov; 20(54):7888-98. PubMed ID: 11753671 [TBL] [Abstract][Full Text] [Related]
19. E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells. Al Moustafa AE; Foulkes WD; Benlimame N; Wong A; Yen L; Bergeron J; Batist G; Alpert L; Alaoui-Jamali MA Oncogene; 2004 Jan; 23(2):350-8. PubMed ID: 14724563 [TBL] [Abstract][Full Text] [Related]
20. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells. Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]